OR WAIT null SECS
Growth and Advancements in Fill/Finish
Employing novel technologies and more patient-centric approaches
Delving into Biopharmaceutical Development and Manufacturing
Quality Considerations in Changing Excipient Providers
February 07, 2024
Purolite and Repligen have commercially launched a new CH1 affinity resin for the purification of specialized mAbs.
February 06, 2024
The addition of another amino acid recognizer as well as improvements in surface chemistry, reagents, and software expand the proteome coverage of Quantum-Si’s Platinum sequencing platform.
February 05, 2024
The CDMOs are joining together to offer end-to-end development and manufacturing services for protein expression systems and viral vectors in Europe.
Novo Holdings has entered into a merger agreement with Catalent and will acquire Catalent in a deal valued at $16.5 billion.
February 04, 2024
NICE has recommended the use of AbbVie's Tepkinly as a treatment option for eligible adults with diffuse large B-cell lymphoma.
February 03, 2024
ProductLife Group has announced its acquisition of Australian company Commercial Eyes.
The emergence of mRNA vaccines and cell and gene therapies has pushed innovation in analytical methods.
This article introduces that the basic technique for tolerance interval is implemented using the conventional range 85–115% LC where the proposed range in the PF is not taken into account.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
Technical, regulatory, and personnel considerations characterize pharmaceutical compounding.